tbuckley/cabot-search huggingface dataset:
Abstract P1-14-12: Response to neoadjuvant chemotherapy and prognosis of primary breast cancer according to intrinsic subtype
Authors: M Kochi, M Ito, S Ohtani, K Higaki
Journal: Cancer Research (2012)

Abstract Background: Response to neoadjuvant chemotherapy of primary breast cancer differs across intrinsic subtypes and is considered as a useful surrogate indicator for prognostic prediction, while some subtype populations seems to take different course. Methods: We classified 364 primary breast cancer patients, who received neoadjuvant chemotherapy after 2002 at our institute, to 5 intrinsic subtype groups; Luminal A type (LA), Luminal B type (LB), Luminal Her2 type (LH), Her2 type (Her2) and triple negative (TN), according to hormonal sensitivity, Her2 status, and cancer proliferation. We evaluated their pathological response to neoadjuvant chemotherapy by response criteria of Japanese Breast Cancer Society. Pathological complete response (pCR) is defined as Necrosis or disappearance of invasive cancer of breast in this study, approving residual non-invasive component of breast or axillary lymph node metastasis. We also examined disease free survival (DFS) and overall survival (OS) by each subtypes statistically, using Kaplan-Meier method and Log-rank test. Results: Number of patients in each subtype were as follows; LA: 141 patients, LB: 41 patients, LH: 38 patients, Her2: 54 patients, and TN: 90 patients. Surveillance period is 4–105 months (median: 37 months). Most of cases in all subtypes received both anthracycline and taxane. 27 cases in LH (71.1%) and 48 cases in Her2 (88.9%) were treated with trastzumab. 7 cases in LA (5.0%), 4 cases in LB (9.8%), 9 cases in LH (23.7%), 31 cases in Her2 (57.4%), and 26 cases in TN (28.9%) achieved pCR. pCR rate was significantly high in Her2 and TN (p &amp;lt; 0.05). LA, LB, LH showed no significant differences in DFS and OS between pCR group and non-pCR group (LA; DFS p = 0.929 OS p = 0.663, LB; DFS p = 0.189 OS p = 0.552, LH; DFS p = 0.508 OS p = 0.691). In Her2 group, pCR group tended to show better prognosis, but there were no significant differences (Her2; DFS p = 0.107, OS p = 0.343). In TN group, pCR group showed significantly better prognosis (TN; DFS p = 0.046, OS p = 0.040), which indicates the correlation between response to neoadjuvant chemotherapy and prognosis. Conclusion: Our results indicate the correlation between response to neoadjuvant chemotherapy and prognosis in TN breast cancer. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-12.
Malignant Neoplastic Disease Discovered in Chest X-Ray Surveys
Authors: Gabriele Bondi, Vera Leites
Journal: New England Journal of Medicine (1952)

AN INCREASING number of publications stress mass x-ray surveys as the best method for the early detection of intrathoracic cancer. This study records our experience concerning the diagnosis and incidence of malignant neoplastic disease found in the course of chest x-ray surveys designed primarily for tuberculosis case finding. The material consisted of surveys conducted by the New York City Department of Health during the calendar years 1949 and 1950. All patients whose survey films showed the need for further work-up were recalled to the Central Chest Clinic of the Department for examination.The surveys were organized on an occupational or . . .
Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment
Authors: N Gangat, M M Patnaik, K Begna, A Al-Kali, M R Litzow, R P Ketterling, C A Hanson, A D Pardanani, A Tefferi
Journal: Blood Cancer Journal (2016)

Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment
Influence of Prognosis on Decisions Regarding the Care of Newborns with Myelodysplasia
Authors: John F. McLaughlin, David B. Shurtleff, Janice Y. Lamers, J. Timothy Stuntz, Patricia W. Hayden, Robert J. Kropp
Journal: New England Journal of Medicine (1985)

Treatment of newborns with myelodysplasia (meningomyelocele and related disorders) continues to be a controversial subject. We have used a consistent plan of care and have employed the same prognostic criteria over the period from 1965 to 1982 to address the needs of 212 affected newborns. A good prognosis and early surgical care were given to 42 per cent of 53 newborns during the period 1965 to 1970, to 58 per cent of 65 newborns from 1971 to 1976, and to 71 per cent of 94 newborns from 1977 to 1982. Of the newborns with an initially poor prognosis, 19 per cent of 31 received early surgery between 1965 and 1970, as compared with 33 per cent of 27 between 1971 and 1976 and 52 per cent of 27 between 1977 and 1982. Life-table analyses of survival in the three periods revealed significant improvement over time in the survival of newboms receiving early surgical care, regardless of the initial prognosis (log-rank statistic = 8.240, P = 0.016) and in comparison to recipients of supportive care alone (log-rank statistic = 5.975, P = 0.05). We conclude that early surgery permits the survival of an increasing percentage of patients with myelodysplasia. (N Engl J Med 1985; 312:1589–94.)
ESCMID guideline: diagnosis and treatment of acute bacterial meningitis
Authors: D. van de Beek, C. Cabellos, O. Dzupova, S. Esposito, M. Klein, A.T. Kloek, S.L. Leib, B. Mourvillier, C. Ostergaard, P. Pagliano, H.W. Pfister, R.C. Read, O. Resat Sipahi, M.C. Brouwer
Journal: Clinical Microbiology and Infection (2016)
Case 22-2009
Authors: Thomas F. Patterson, Bonnie T. Mackool, Matthew D. Gilman, Adriano Piris
Journal: New England Journal of Medicine (2009)

A 59-year-old man was admitted to this hospital for induction chemotherapy for acute myeloid leukemia. On the seventh hospital day, neutropenia, fever, nausea, diarrhea, and abdominal pain developed. Despite the administration of broad-spectrum antimicrobial therapy, tender, erythematous skin lesions developed on the trunk, abdomen, and arms and legs, and bilateral pulmonary nodules were seen on computed tomographic scans of the chest. A diagnostic procedure was performed.
Lymphocyte Mitogen Reactivity and Enumeration of Circulating B- and T-Cells During Feline Leukemia Virus Infection in the Cat23
Authors: G. L. Cockerell, E. A. Hoover, S. Krakowka, R. G. Olsen, D. S. Yohn
Journal: JNCI Journal of the National Cancer Institute (1976)

Mitogen-induced blast transformation of peripheral blood lymphocytes and quantitative changes in circulating T- and B-cells were studied serially in cats inoculated with feline leukemia virus (FeLV). Concanavalin A-induced blast transformation sharply declined beginning at 5 weeks post inoculation (PI) in FeLV-infected cats when compared to age-matched uninfected control cats. Similar but less consistent changes were seen in responses to pokeweed mitogen-induced stimulation. In most infected kittens this defect persisted until they died from thymic lymphosarcoma, 15–24 weeks PI. An early lymphopenia, due primarily to a decrease in circulating B-cells, occurred in infected cats 5–8 weeks PI. Following a return of total and B-lymphocytes to control values, infected cats developed increased numbers of T-cells at 16 or more weeks PI, which correlated with circulating lymphoblastic lymphocytes bearing T-cell markers. These results correlated neoplasia arising in a thymus-derived lymphocyte population with mitogenic hyporeactivity in the preneoplastic period and suggested that FeLV-induced immune alterations may be a necessary antecedent of leukemogenesis in the cat.
An Acute Dystonic Reaction after Treatment with Metoclopramide
Authors: Manon Leus, Annenienke van de Ven
Journal: New England Journal of Medicine (2015)

A 21-year-old woman with thyroid carcinoma underwent thyroidectomy and lymph-node dissection. Two days later, she had forced extension of the neck, nonrigid opening of the jaw, and deviation of the eyes. Videos show the reaction and the resolution after treatment with biperiden.
Direct Diagnosis by DNA Analysis of the Fragile X Syndrome of Mental Retardation
Authors: François Rousseau, Dominique Heitz, Valérie Biancalana, Sandra Blumenfeld, Christine Kretz, Joëlle Boué, Niels Tommerup, Carl Van Der Hagen, Célia DeLozier-Blanchet, Marie-Françoise Croquette, Simone Gilgenkrantz, Pierre Jalbert, Marie-Antoinette Voelckel, Isabelle Oberlé, Jean-Louis Mandel
Journal: New England Journal of Medicine (1991)

The fragile X syndrome, the most common form of inherited mental retardation, is caused by mutations that increase the size of a specific DNA fragment of the X chromosome (in Xq27.3). Affected persons have both a full mutation and abnormal DNA methylation. Persons with a smaller increase in the size of this DNA fragment (a premutation) have little or no risk of retardation but are at high risk of having affected children or grandchildren. The passage from premutation to full-mutation status occurs only with transmission from the mother. We have devised a method of identifying carriers of these mutations by direct DNA analysis.We studied 511 persons from 63 families with the fragile X syndrome. Mutations and abnormal methylation were detected by Southern blotting with a probe adjacent to the mutation target. Analysis of EcoRI and EagI digests of DNA distinguished clearly in a single test between the normal genotype, the premutation, and the full mutation.DNA analysis unambiguously established the genetic status at the fragile X locus for all samples tested. This method was much more powerful and reliable than cytogenetic testing or segregation studies with closely linked polymorphic markers. The frequency of mental retardation in persons with premutations was similar to that in the general population, whereas all 103 males and 31 of 59 females with full mutations had mental retardation. About 15 percent of those with full mutations had some cells carrying only the premutation. All the mothers of affected children were carriers of either a premutation or a full mutation.Direct diagnosis by DNA analysis is now an efficient and reliable primary test for the diagnosis of the fragile X syndrome after birth, as well as for prenatal diagnosis and genetic counseling.
PT-12 * SURGICAL APPROACH FOR THALAMIC TUMORS
Authors: M. Smrcka, V. Priban, E. Brichtova, V. Juran
Journal: Neuro-Oncology (2014)

INTRODUCTION: Thalamic tumors are relatively rare tumors growing in a highly functional part of brain. They are more frequent in pediatric population. Their surgery is challenging and a high morbidity is possible. Relatively benign nature of many of these tumors means that an attempt for radical resection should frequently be performed. The approach has to be very carefully planned, sometimes with the help of modern diagnostic methods like DTI. The location and projection of the tumor in the thalamus plays an important role in choosing the approach. MATERIAL: We have studied a group of 12 patients with thalamic tumors treated from 2005 - 2012. There were 10 males and 2 females, age ranged from 1 - 64 years (mean 17,5 years). Transcortical approach was used 6x, transcallosal 3x, transsylvian 2x and supracerebellar infratentorial 1x. One patient is being observed only. RESULTS: Gross total resection was achieved in 6 cases, subtotal in 2 and partial in 3. There were 7 pilocytic astrocytomas, one subependymal giant cell astrocytoma, one diffuse astrocytoma G II and two glioblastomas. All patients are still alive with the mean follow-up 4 years. There was no permanent morbidity in this group. CONCLUSION: Thalamic tumors might be safely radically resected if correct approach is used. The choice of approach is based in the projection of the tumor. Smaller tumors which are not close to the thalamic surface might be followed or biopsied if there is a likelihood of its malignant nature. Oncological treatment should be reserved for malignant tumors.
A4.2 IL4–10 synerkine for the treatment of osteoarthritis
Authors: C Steen-Louws, MF Pustjens, SC Mastbergen, CE Hack, JAG van Roon, FPJG Lafeber
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background and objectives</h3> Osteoarthritis (OA) is a degenerative joint disease, clinically characterised by joint pain and disability. Underlying structural changes are degeneration of articular cartilage, intra-articular inflammation with synovitis and changes in peri-articular and subchondral bone. The ideal drug to treat OA should have analgesic, anti-inflammatory and cartilage protective effects. To date, no such drug has been described. In human and animal <i>in</i> and <i>ex-vivo</i> models, the immunoregulatory cytokines interleukin 4 (IL-4) and interleukin 10 (IL-10), especially in combination therapy, can prevent joint degeneration effectively. To use the combined activities of both IL-4 and IL-10, we developed IL4–10 synerkine, preserving the functional activity of each cytokine. In several well-established animal models, we have shown the potential of IL4–10 synerkine to inhibit inflammatory pain in animal models. In this study, we evaluated the potential of the synerkine to reduce inflammation and to provide cartilage protection in an <i>ex vivo</i> model for human OA. <h3>Materials and methods</h3> Osteoarthritic cartilage (n = 8) and synovium (n = 6) was obtained at joint replacement surgery and was cultured for 72 h in conditioned medium, in the presence or absence of equimolar concentrations of IL-4 (10 ng/ml), IL-10 (10 ng/ml), the combination of IL-4 and IL-10 (10 ng/ml + 10 ng/ml) and IL4-10 synerkine (20 ng/ml). After culture, cartilage was selected to study changes in proteoglycan (PG) synthesis and release. Supernatants of both cartilage and synovium cultures were collected for measurement of a broad spectrum of inflammatory mediators. <h3>Results</h3> In both synovium and cartilage cultures, elevated levels of pro-inflammatory mediators like IL-6 (resp. 7.5 µg/mg and 531 µg/mg) and IL-8 (resp. 2.6 µg/mg and 142 µg/mg) were measured. These levels were strongly inhibited by the IL4-10 synerkine (about 80%; all p &lt; 0.01). IL4-10 synerkine also showed a reducing effect on the release of other important mediators, like IL-1, MMP-1 and MMP-3, whereas levels of interleukin-1 receptor antagonist (IL-1RA) and tissue inhibitor of metalloproteinase-1 (TIMP-1) remained unchanged. Additionally, the synerkine had a beneficial effect on proteoglycan metabolism, inducing proteoglycan synthesis with 32%, while the proteoglycan release was slightly reduced (-1.3%). <h3>Conclusions</h3> IL4-10 synerkine directly affects proteoglycan turnover and cytokine production of OA cartilage, combined with reduced secretion of inflammatory cytokines and proteases by OA synovial tissue. The immunoregulatory and cartilage protective effects in combination with it’s analgesic effects, suggest that the synerkine is an effective disease modifying drug in the treatment of osteoarthritis.
Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial
Authors: Srdan Verstovsek, Jean-Jacques Kiladjian, Martin Griesshammer, Tamás Masszi, Simon T. S. Durrant, Francesco Passamonti, Claire N. Harrison, Fabrizio Pane, Pierre Zachee, Ruben A. Mesa, Shui He, Mark Jones, William M. Garrett, Jingjin Li, Ulrich Pirron, Tomasz Lawniczek, Alessandro M Vannucchi
Journal: Journal of Clinical Oncology (2014)

7026 Background: PV is a myeloproliferative neoplasm characterized by increased erythrocytosis, disease-related symptom burden (eg, pruritus), and risk of vascular events (thrombosis and/or hemorrhage). Maintaining hematocrit (HCT) control is a key therapeutic goal. RESPONSE is the first phase 3 study to evaluate a JAK inhibitor (RUX) in treating PV. Methods: Phlebotomy (PBT)-dependent patients (pts) with splenomegaly (> 450 cm3) and HU resistance/intolerance were randomized 1:1 to RUX 10 mg bid or best available therapy (BAT). The primary endpoint was the proportion of pts who achieved both HCT control without PBT from wk 8 to 32 (with ≤ 1 PBT from wk 0 to 8) and a ≥ 35% reduction in spleen volume (SV) from baseline (BL) by MRI at wk 32. Key secondary endpoints included the proportion of pts who maintained the primary response at wk 48 and the proportion of pts who achieved complete hematologic response (CHR) at wk 32. Other endpoints were duration of response, symptom improvement by MPN-SAF diary, and safety. BAT-treated pts could cross over to RUX from wk 32. The primary analysis occurred when all pts reached wk 48 or discontinued. Results: 110 and 112 pts were randomized to RUX and BAT, respectively (median exposure: RUX, 81 wk; BAT, 34 wk); 17 (15%) RUX and 108 (96%) BAT pts discontinued randomized treatment (96 crossed over to RUX). The primary endpoint was achieved in 21% of RUX vs 1% of BAT pts (P < .0001); 91% of RUX pts maintained their response at wk 48. Overall, 77% of RUX pts met ≥ 1 component of the primary endpoint: 60% of RUX and 20% of BAT pts achieved HCT control without PBT; 38% of RUX and 1% of BAT pts achieved a ≥ 35% SV reduction (median BL SV, 1195 cm3 in RUX and 1322 cm3 in BAT pts). CHR was achieved in 24% and 9% of RUX and BAT pts (P = .003); 49% vs 5% had a ≥ 50% improvement in MPN-SAF 14-item total symptom score at wk 32. During the first 32 wk, grade 3/4 anemia or thrombocytopenia occurred in 1.8% and 5.5% of RUX pts, respectively, vs 0% and 3.6% of BAT pts; thromboembolic events occurred in 1 RUX and 6 BAT pts. Conclusion: RUX was well tolerated and superior to BAT in controlling HCT without PBT and reducing SV. RUX was also effective in improving PV-associated symptoms. Clinical trial information: NCT01243944.
Abstract P3-12-09: Numb Expression Varies by Hormone Receptor Status among Danish Breast Cancer Patients
Authors: W Zhou, B Rasmussen, M Busch-Sørensen, T Demuth, J Reilly, D Bergstrom, J Pearson, S Møller, B. Ejlertsen
Journal: Cancer Research (2010)

Abstract Background: Numb-mediated regulation of Notch signaling pathway might play a causative role in early breast cancer. Little information is available on whether Numb expression differs according to tumor characteristics including hormone receptor status. We investigated Numb expression status in archival tissue from primary tumor of 197 breast cancer patients identified within the 2004 cohort of the Registry of the Danish Breast Cancer Cooperative Group's (DBCG), where patients were treated according to the guidelines of the DBCG. Materials and Methods: Numb expression was measured by immunohistochemistry method, and Numb(-) was defined as Numb immunoreactivity present in less than 10% of the invasive tumor cells. Chi-square test was used to assess the correlation between Numb(-) and hormone receptor status. Results: The median age was 57 years (range, 26-98), 32% were premenopausal. 82% were ductal, 9% lobular, 9% others. 10% were grade I, 41% grade II, 47% grade III, 2% non-graded. 70% were node positive. 60% were ER+, 41% PR+, and 24% were HER2+ by IHC and FISH. 58% were operated by mastectomy, 42% by lumpectomy. The adjuvant treatment comprised Tamoxifen (36%), cyclophosphamide/methotrexate/fluorouracil (CEF, 19%), CEF+Tamoxifen (11%), and 22% were missing treatment information. 49% relapsed and 3% metastasized during 10 year of follow up. Overall, 10% (19 out of 197) of patients were Numb(-). Numb expression was significantly associated with hormone status, with a Numb(-) frequency of 24% (9/37) among ER+/PR-/HER2-, 9% (6/65) among ER+/PR+/HER2-, 6% (3/47) among HER+ (1/16 among ER+/PR+/HER2+ and 2/31 among ER-/PR-/HER2+), and 2% (1/47) among ER-/PR-/HER2- patients (P&amp;lt;0.01). Similar differences were observed using the H-score matrix where the IHC intensity was summarized with a range of 0-300. Discussion: Our results suggested Numb(-) is correlated with hormone status, with the higher frequency of Numb(-) among ER+/PR-/HER2- patients, and lower frequency among other groups, particularly the triple negative group. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-12-09.
Comparison of endoscopic submucosal dissection with laparoscopic-assisted colorectal surgery for early-stage colorectal cancer: a retrospective analysis
Authors: S. Kiriyama, Y. Saito, S. Yamamoto, R. Soetikno, T. Matsuda, T. Nakajima, H. Kuwano
Journal: Endoscopy (2012)

<b>Background and study aims:</b> Endoscopic submucosal dissection (ESD) is increasingly being used to resect early colorectal carcinoma, despite the technical difficulties associated with the procedure. Laparoscopic-assisted colorectal surgery (LAC) is an alternative to open surgery for colorectal cancers, and ESD was recently introduced as another alternative. In this study, we compared ESD with LAC as minimally invasive treatments for early colorectal cancer. <b>Patients and methods:</b> The study included 589 patients (297 patients with colorectal intramucosal or slightly submucosal invasive cancers undergoing ESD; 292 patients with T1 colorectal cancers undergoing LAC) who were treated at National Cancer Center Hospital in Tokyo, Japan, between January 1998 and September 2008. The clinical outcomes of ESD and LAC were evaluated retrospectively and compared on the basis of data that were originally collected prospectively. <b>Results:</b> In the ESD group, mean tumor size was 37 mm, mean procedure time was 106 minutes, and the en bloc and curative resection rates were 87 % and 80 %, respectively. There were 14 perforations (4.7 %) and 5 cases of postprocedure bleeding (1.7 %); all complications were successfully managed endoscopically except for one of the perforations, which required emergency surgery. In the LAC group, mean tumor size was 20 mm, mean operation time was 206 minutes, and complications included 31 wound infections, 2 pelvic abscesses, 3 anastomotic leakages, and 1 anastomotic bleed. Stomas were necessary in 93 % of the patients who underwent LAC for rectal cancers located below the peritoneal reflection. <b>Conclusions:</b> ESD was associated with a lower complication rate than LAC, with favorable en bloc and curative resection rates. The safety profile and possibility of curative treatment with colorectal ESD provide advantages for the treatment of early colorectal cancers with nul risk of lymph node metastasis.
Cardiopulmonary Thromboembolism Detected by Tc-99m MH-1 Antifibrin Antibody
Authors: BRUCE R. LINE, JAMES F. KEENAN, ROBERTA L. LUKASIEWICZ, RAYMOND N. DANSEREAU, MITCHELL E. TUBLIN, LINDA M. WILLIAMS, PAUL E. GARGAN
Journal: Clinical Nuclear Medicine (1997)

A patient with shortness of breath had a high probability lung scan for pulmonary embolism, but no obvious embolic source. Whole-body scintigraphy using Tc-99m labeled Fab' antifibrin monoclonal antibody showed large central pulmonary emboli as well as tracer uptake in the right atrium and aortic arch. No lower extremity clot was detected. This case shows significant differences in the appearance of pulmonary embolism as assessed by direct clot and ventilation-perfusion scintigraphy. It shows the importance of the heart as the origin of pulmonary emboli and the utility of direct thrombus visualization.